#AAIC21 – BIIB080 Safely Lowered Tau Levels in Patients in Phase 1 Trial

#AAIC21 – BIIB080 Safely Lowered Tau Levels in Patients in Phase 1 Trial

302938

#AAIC21 – BIIB080 Safely Lowered Tau Levels in Patients in Phase 1 Trial

BIIB080, an investigational therapy for Alzheimer’s disease, was safe and well-tolerated, and sustainably lowered patients’ levels of tau — a protein linked to neurodegeneration, according to topline results of a Phase 1b clinical trial. “There is clearly an urgent need to develop and deliver effective treatments for Alzheimer’s disease, a devastating disorder for which there currently are limited therapeutic options,” C. Frank Bennett, PhD, Ionis’ chief scientific officer, said in a press release. Ionis Pharmaceuticals…

You must be logged in to read/download the full post.